fda drug safety communication naion semaglutide 2025 National Hispanic Medical Association | After compounded GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and FDA Warns Novo Nordisk of

And because compounding pharmacies arent required to report instances of patient harm involving their medications, problems may go undetected

While Rybelsus is primarily approved for the treatment of type 2 diabetes, many patients experience weight loss as a secondary benefit

Ongoing Monitoring & Adjustments Follow-up appointments allow for safe dose optimization and long-term success

Less often, patients report headaches, tiredness, or dizziness

no completed modern RCT

The Science of Weight Regain Perhaps the most documented side effect of stopping semaglutide is weight regain, with a landmark study reporting that two-thirds of those who discontinue regain all the lost weight within one year